ArticleHereditary cancer in clinical practice2021

Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review.

Tong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.